Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9754562rdf:typepubmed:Citationlld:pubmed
pubmed-article:9754562lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:9754562lifeskim:mentionsumls-concept:C1518997lld:lifeskim
pubmed-article:9754562lifeskim:mentionsumls-concept:C0034790lld:lifeskim
pubmed-article:9754562lifeskim:mentionsumls-concept:C0014072lld:lifeskim
pubmed-article:9754562lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:9754562lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:9754562lifeskim:mentionsumls-concept:C1709630lld:lifeskim
pubmed-article:9754562pubmed:issue9lld:pubmed
pubmed-article:9754562pubmed:dateCreated1998-10-13lld:pubmed
pubmed-article:9754562pubmed:abstractTextIn organ-specific autoimmune diseases, T cells involved in the disease development bear a particular type of TCR and infiltrate the target organ predominantly. However, it is difficult to identify disease-inducing T cells in peripheral blood lymphocytes (PBL) because such T cells are very few in number in a large pool of unrelated T cells. In the present study, we demonstrate that CDR3 spectratyping can identify experimental autoimmune encephalomyelitis (EAE)-specific patterns (oligoclonal expansion of Vbeta8.2 with the shortest CDR3) in PBL at the preclinical and clinical stages of acute EAE. Analysis of nucleotide and predicted amino acid sequences of Vbeta8.2 CDR3 of spectratype-derived clones revealed that CASSDSSYEQYFGPG, which is one of the representative sequences of encephalitogenic T cell clones, constituted the predominant population in both PBL and spinal cord T cells. In chronic relapsing EAE, the EAE-specific spectratype pattern in PBL was observed during the 1 st and 2nd attacks, but not at the remission and full recovery stage. These findings indicate that the spectratyping pattern in PBL reflects the disease activity of acute and chronic relapsing EAE. Thus, CDR3 spectratyping using PBL can be used for diagnosis and assessment of T cell-mediated autoimmune diseases and is applicable to human autoimmune diseases.lld:pubmed
pubmed-article:9754562pubmed:languageenglld:pubmed
pubmed-article:9754562pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9754562pubmed:citationSubsetIMlld:pubmed
pubmed-article:9754562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9754562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9754562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9754562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9754562pubmed:statusMEDLINElld:pubmed
pubmed-article:9754562pubmed:monthSeplld:pubmed
pubmed-article:9754562pubmed:issn0014-2980lld:pubmed
pubmed-article:9754562pubmed:authorpubmed-author:MatsumotoYYlld:pubmed
pubmed-article:9754562pubmed:authorpubmed-author:KimGGlld:pubmed
pubmed-article:9754562pubmed:authorpubmed-author:KohyamaKKlld:pubmed
pubmed-article:9754562pubmed:authorpubmed-author:TanumaNNlld:pubmed
pubmed-article:9754562pubmed:issnTypePrintlld:pubmed
pubmed-article:9754562pubmed:volume28lld:pubmed
pubmed-article:9754562pubmed:ownerNLMlld:pubmed
pubmed-article:9754562pubmed:authorsCompleteYlld:pubmed
pubmed-article:9754562pubmed:pagination2751-9lld:pubmed
pubmed-article:9754562pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:meshHeadingpubmed-meshheading:9754562-...lld:pubmed
pubmed-article:9754562pubmed:year1998lld:pubmed
pubmed-article:9754562pubmed:articleTitleDiagnosis and assessment of preclinical and clinical autoimmune encephalomyelitis using peripheral blood lymphocyte TCR.lld:pubmed
pubmed-article:9754562pubmed:affiliationDepartment of Neuropathology, Tokyo Metropolitan Institute for Neuroscience, Fuchu City, Japan.lld:pubmed
pubmed-article:9754562pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9754562pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed